clinical trial · NCT05724446
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
Salvat·phase3·recruiting·n = 60
Cataracts InfantileClobetasol PropionatePrednisolone acetate ophthalmic suspension, 1%
brief summary
Multicenter, randomized, evaluator-blinded clinical trial compared to Prednisolone acetate, 1% in the treatment of inflammation and pain after cataract surgery in pediatric population. This study will assess the safety of Clobetasol propionate ophthalmic nanoemulsion, 0.05% to that of Prednisolone acetate, 1% when administering one drop four times a day (QID) for 14 days followed by a tapering period of 14 days after cataract surgery.
started
Dec 12, 2022
primary completion
Dec 31, 2025
completion
Dec 31, 2025
last updated
Sep 27, 2024
official title
A Phase 3, Multicenter, Randomized, Evaluator-blinded Clinical Trial to Assess the Safety and Efficacy of Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% Compared to Prednisolone Acetate, 1% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population 0 to 3 Years of Age (CLOSE-3)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol